Ainos, Inc.
AIMD
NASDAQ·Healthcare·Biotechnology·Mkt cap $10.0M
$1.30
▲ +2.36%
P/E
—
Mkt Cap
$10.0M
52-Wk Range
$1.20–$4.44
52-Week Range
$1.20 - $4.44
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 65.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary low-dose oral interferon alpha formulation with broad therapeutic applications
- Integrated cloud-based diagnostic platform combining hardware and software solutions
- Established point-of-care testing expertise and rapid deployment capabilities
- Synthetic RNA technology platform with potential for multiple therapeutic indications
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
No forward estimates available
Expansion of point-of-care diagnostic testing into new markets and disease indications
Value
Valuation data unavailable
Momentum
Falling
-33.7% over 3m
Quality
Below
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying AIMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 3, 2026
Most recent quarter reported revenue of $152 (-97% YoY). Reported EPS of -$0.62. Gross margin 65.1%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
+412%
—
—
—
-97%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q2 26
$0
$0
$0
$106.2K
$4.7K
$2.2K
$11.1K
$152
Margins · last 8Q
Gross
65.1%
Profit
-3022849.3%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How AIMD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related